BRAF and colorectal carcinoma: In BRAF V600E-mutant CRC, adaptive resistance to BRAF/EGFR inhibitors is achieved through the upregulation of GPX4, with the upstream mechanism involving the Polo-like kinase 1 (PLK1) signaling axis [98].